Human Nrf2 Reporter Assay Kit

SIZE SKU PRICE
1 x-96 well format assays$860 USD
3 x-32 assays in-96 well format$930 USD
1 x-384 well format assays$2185 USD
SIZE SKU
1 x-96 well format assays
3 x-32 assays in-96 well format
1 x-384 well format assays

Product Description and Product Data

This is an all-inclusive cell-based luciferase reporter assay kit targeting the Human Nuclear Factor (erythroid-derived 2)-like 2 Receptor (Nrf2). INDIGO’s Nrf2 reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of Nrf2. In addition to Nrf2 Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human Nrf2. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture.

Features

  • Clear, Reproducible Results

  • All-Inclusive Assay Systems
  • Exceptional Cell Viability Post-Thaw
  • Consistent Results Lot to Lot

Product Specifications

Target TypeNuclear Hormone Receptor
SpeciesHuman
Receptor FormNative
Assay ModeAgonist, Antagonist
Kit Components
  • Nrf2 Reporter Cells
  • Cell Recovery Medium (CRM)
  • Compound Screening Medium (CSM)
  • CDDO Im, (ref. agonist; in DMSO)
  • Detection Substrate
  • Detection Buffer
  • White, sterile, cell-culture ready assay plate
Shelf Life6 months
Orthologs AvailableNo
Shipping RequirementsDry Ice
Storage temperature-80C

Data

Agonist dose-response analyses of Human Nrf2. Agonist analyses of Human Nrf2 Reporter Cells were performed according to the protocol described in this Technical manual, using the reference agonists CDDO Im (provided), L-Sulforaphane (Tocris), and t-BHQ (t-butyl hydroquinone; Enzo). Average values of fold-activation of Nrf2 and Z’ were calculated as described by Zhang, et al. (1999). Non-linear regression and EC50 analyses were performed using GraphPad Prism software. The reference agonist t-BHQ yielded a Z' value of 0.79, confirming the robust performance of this assay and its suitability for HTS.

Target Background

Nrf2 is a ubiquitously expressed, basic leucine zipper transcription factor. It regulates the expression of a variety of genes encoding proteins that play critical roles in cyto-protection, as well as the detoxification and clearance of harmful endogenous and xenobiotic substances. In particular, Nrf2 regulates the expression of antioxidant proteins that confer cyto-protection against oxidative damage.

Under normal conditions Nrf2 resides in the cytoplasm bound to Keap1 and Cullin 3, and is the target of ubiquitination and rapid turn-over via proteasomal degradation. However, under conditions of cellular oxidative stress the tight association of Nrf2 with Keap1 and Cullin 3 is broken, effectively disrupting the otherwise efficient process of Nrf2 degradation. Once non-ubiquitinated Nrf2 accumulates in the cytoplasm it translocates into the nucleus, whereupon it forms hetero-dimers with Maf. In this configuration Nrf2 binds to antioxidant response element (ARE) sequences resident in the promoter regions of some genes, initiating transcription complex formation and gene expression.

INDIGO’s Human Nrf2 utilizes proprietary mammalian cells that include the luciferase reporter gene functionally linked to a promoter containing tandem antioxidant response elements (AREs) and engineered to provide constitutive, high-level expression of Human Nrf2.

The principal application of this reporter assay system is in the screening of test samples to quantify functional activity, either agonist or antagonist, that may exert against Human Nrf2.

Citations

Regeneration of myelin is mediated by oligodendrocyte progenitor cells (OPCs), an abundant stem cell population in the CNS and the principal source of new myelinating oligodendrocytes. Loss of myelin-producing oligodendrocytes in the central nervous system (CNS) underlies a number of neurological diseases, including multiple sclerosis (MS) and diverse genetic diseases1–3. Using high throughput chemical screening approaches, we and others have identified small molecules that stimulate oligodendrocyte formation from OPCs and functionally enhance remyelination in vivo4–10. Here we show a broad range of these pro-myelinating small molecules function not through their canonical targets but by directly inhibiting CYP51 (cytochrome P450, family 51), TM7SF2, or EBP (emopamil binding protein), a narrow range of enzymes within the cholesterol biosynthesis pathway. Subsequent accumulation of the 8,9-unsaturated sterol substrates of these enzymes is a key mechanistic node that promotes oligodendrocyte formation, as 8,9-unsaturated sterols are effective when supplied to OPCs in purified form while analogous sterols lacking this structural feature have no effect. Collectively, our results define a unifying sterol-based mechanism-of-action for most known small-molecule enhancers of oligodendrocyte formation and highlight specific targets to propel the development of optimal remyelinating therapeutics.
2018-07-25

Also available as a service

Nuclear Factor (erythroid-derived 2)-like 2 (Nrf2)